Illumina (ILMN) Lifted to Buy at BidaskClub

BidaskClub upgraded shares of Illumina (NASDAQ:ILMN) from a hold rating to a buy rating in a research note issued to investors on Friday morning.

A number of other analysts have also recently issued reports on ILMN. Evercore ISI assumed coverage on shares of Illumina in a research note on Wednesday, January 3rd. They issued an outperform rating and a $250.00 target price for the company. BTIG Research assumed coverage on shares of Illumina in a research note on Friday. They issued a neutral rating for the company. Goldman Sachs Group reiterated a neutral rating and issued a $200.00 target price on shares of Illumina in a research note on Tuesday, September 26th. Piper Jaffray Companies lifted their target price on shares of Illumina to $274.00 and gave the company an overweight rating in a research note on Thursday. Finally, Canaccord Genuity reiterated a buy rating and issued a $230.00 target price (up from $215.00) on shares of Illumina in a research note on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $211.88.

Illumina (ILMN) traded down $1.11 during midday trading on Friday, reaching $227.06. 1,000,000 shares of the company’s stock were exchanged, compared to its average volume of 842,922. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. The firm has a market capitalization of $33,150.00, a PE ratio of 42.84, a PEG ratio of 3.13 and a beta of 0.79. Illumina has a 1 year low of $137.40 and a 1 year high of $233.54.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s revenue was up 17.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.97 earnings per share. analysts expect that Illumina will post 3.75 EPS for the current fiscal year.

In related news, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction on Saturday, December 29th. The shares were sold at an average price of $217.38, for a total transaction of $271,725.00. Following the transaction, the director now owns 8,838 shares of the company’s stock, valued at $1,921,204.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $203.27, for a total transaction of $4,065,400.00. The disclosure for this sale can be found here. Insiders have sold 158,921 shares of company stock worth $33,810,181 in the last ninety days. 0.89% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in ILMN. Winslow Capital Management LLC bought a new stake in Illumina in the 2nd quarter valued at $211,584,000. Fred Alger Management Inc. increased its holdings in Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after buying an additional 548,030 shares during the period. TIAA CREF Investment Management LLC increased its holdings in Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares during the period. Capital World Investors increased its holdings in Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares during the period. Finally, Janus Henderson Group PLC increased its holdings in Illumina by 1,556.2% in the 2nd quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock valued at $57,263,000 after buying an additional 310,084 shares during the period. 91.60% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Illumina (ILMN) Lifted to Buy at BidaskClub” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/08/illumina-ilmn-lifted-to-buy-at-bidaskclub.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

What are top analysts saying about Illumina? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit